These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38023174)

  • 1. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
    Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
    Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
    Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
    Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
    Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
    J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
    Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
    PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
    Heeg E; Marang-van de Mheen PJ; Van Maaren MC; Schreuder K; Tollenaar RAEM; Siesling S; Bos MEMM; Vrancken Peeters MTFD
    Int J Cancer; 2020 Jul; 147(1):152-159. PubMed ID: 31721193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
    Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
    Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
    Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
    JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
    Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
    Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease.
    Pinto JA; Araujo J; Cardenas NK; Morante Z; Doimi F; Vidaurre T; Balko JM; Gomez HL
    NPJ Genom Med; 2016; 1():15015. PubMed ID: 29263808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.
    Sun W; Li C; Liu M; Liu W; Yang C; Cai LI
    Oncol Lett; 2016 Mar; 11(3):2320-2326. PubMed ID: 26998170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.
    Tang Z; Ji Y; Min Y; Zhang X; Xu W; Zhao L; Zhang J; Long L; Feng J; Wen Y
    Front Endocrinol (Lausanne); 2022; 13():856268. PubMed ID: 35370936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.
    Sheng DL; Shen XG; Shi ZT; Chang C; Li JW
    Eur Radiol; 2022 Oct; 32(10):6575-6587. PubMed ID: 35759017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
    BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
    Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
    Gelber RD; Wang XV; Cole BF; Cameron D; Cardoso F; Tjan-Heijnen V; Krop I; Loi S; Salgado R; Kiermaier A; Frank E; Fumagalli D; Caballero C; de Azambuja E; Procter M; Clark E; Restuccia E; Heeson S; Bines J; Loibl S; Piccart-Gebhart M;
    Eur J Cancer; 2022 May; 166():219-228. PubMed ID: 35313167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With
    Wang Z; Wang H; Sun X; Fang Y; Lu SS; Ding SN; Chen XS; Shen KW
    Front Oncol; 2020; 10():14. PubMed ID: 32038988
    [No Abstract]   [Full Text] [Related]  

  • 20. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
    Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
    Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.